|
WO2021081055A1
|
|
In-line product monitoring in integrated continuous bio-manufacturing
|
|
US2021087514A1
|
|
Product quality attribute measurement
|
|
WO2021016571A2
|
|
Methods of treating antibody-mediated disorders with fcrn antagonists
|
|
WO2020243502A1
|
|
Two-dimensional lc-ms/ms systems
|
|
WO2020227364A1
|
|
Methods for quantifying drug concentration in a prodrug composition
|
|
WO2020206063A1
|
|
Anti-alpha beta tcr binding polypeptides with reduced fragmentation
|
|
TW202102519A
|
|
Continuous production of recombinant proteins
|
|
WO2020185825A1
|
|
Tangential viral filtration
|
|
WO2020163337A1
|
|
Treatment of ciliopathies using inhibitors of glucosylceramide synthase (gcs)
|
|
WO2020163245A1
|
|
Methods for treating symptoms and disorders associated with lysosomal storage diseases
|
|
WO2020150431A1
|
|
Serpinc1 irna compositions and methods of use thereof
|
|
WO2020077250A1
|
|
Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy
|
|
CA3114722A1
|
|
Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use
|
|
AU2019222801B2
|
|
Glucosylceramide synthase inhibitors
|
|
WO2020046602A1
|
|
Sterile chromatography resin and use thereof in manufacturing processes
|
|
WO2020028816A1
|
|
Variant rnai against alpha-synuclein
|
|
UY38238A
|
|
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACID SPHINGOMYELINASE DEFICIENCY
|
|
TW202003832A
|
|
Perfusion bioreactor with filtration systems
|
|
EP3765846A1
|
|
Methods for improving cell viability in a production bioreactor
|
|
AU2019226568A1
|
|
Multivariate spectral analysis and monitoring of biomanufacturing
|
